BEAM Beam Therapeutics Inc.
BEAM Beam Therapeutics Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-14 1 neutral converging
POC $26.46 · VWAP $26.83 · +1.0% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
2 watchlists
BEAM Price Structure
Loading timeframes…
Peers
Every watchlist BEAM belongs to, members best 30-day change first — BEAM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
Reported the quarter ending 2026-03-31: revenue $32M, diluted EPS $-0.91, net income $-94M (SEC filing). Across the print the stock moved +8.9% (close before → first close after).
full note →Against street estimates
How BEAM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about BEAM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 42 days ago · Jul 7
- Beam Therapeutics' stock was trading at $27.72 at the beginning of 2026. Since then, BEAM shares have increased by 25.5% and is now trading at $34.79.
- Beam Therapeutics posted Q1 2026 earnings on May 7, 2026, reporting an EPS of $-0.91, which topped the consensus estimate of $-1.03 by $0.12.
- Beam Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:BEAM
- BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024
BEAM research tape
47 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.